In contrast, pharmacological activation of BCAA catabolism using sodium phenylbutyrate reduces plasma BCAA and glucose levels, improves peripheral insulin sensitivity, and enhances muscle mitochondrial oxidative capacity in individuals with Type 2 diabetes [26]. This evidence concerns the gene INS and type 2 diabetes mellitus.